Tributary Capital Management LLC boosted its stake in shares of AngioDynamics, Inc. (NASDAQ:ANGO) by 1.4% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 503,670 shares of the medical instruments supplier’s stock after purchasing an additional 6,895 shares during the period. Tributary Capital Management LLC owned about 1.36% of AngioDynamics worth $10,139,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Wells Fargo & Company MN grew its position in AngioDynamics by 2.0% during the third quarter. Wells Fargo & Company MN now owns 1,103,646 shares of the medical instruments supplier’s stock valued at $23,993,000 after purchasing an additional 21,218 shares in the last quarter. Nordea Investment Management AB lifted its stake in AngioDynamics by 27.8% in the third quarter. Nordea Investment Management AB now owns 208,523 shares of the medical instruments supplier’s stock valued at $4,533,000 after acquiring an additional 45,410 shares during the last quarter. Acadian Asset Management LLC lifted its stake in AngioDynamics by 15.8% in the third quarter. Acadian Asset Management LLC now owns 302,068 shares of the medical instruments supplier’s stock valued at $6,568,000 after acquiring an additional 41,279 shares during the last quarter. Heartland Advisors Inc. lifted its stake in AngioDynamics by 41.0% in the third quarter. Heartland Advisors Inc. now owns 503,827 shares of the medical instruments supplier’s stock valued at $10,953,000 after acquiring an additional 146,498 shares during the last quarter. Finally, WINTON GROUP Ltd acquired a new stake in AngioDynamics in the third quarter valued at approximately $1,528,000. 98.80% of the stock is currently owned by hedge funds and other institutional investors.
ANGO has been the subject of a number of analyst reports. BidaskClub upgraded shares of AngioDynamics from a “buy” rating to a “strong-buy” rating in a research note on Friday, September 28th. Canaccord Genuity lifted their target price on shares of AngioDynamics from $20.00 to $23.00 and gave the company a “hold” rating in a research note on Monday, January 7th. Finally, Zacks Investment Research upgraded shares of AngioDynamics from a “hold” rating to a “strong-buy” rating and set a $24.00 target price for the company in a research note on Wednesday. Two research analysts have rated the stock with a hold rating, two have given a buy rating and two have issued a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $21.11.
In other news, CFO Michael Greiner sold 1,939 shares of the business’s stock in a transaction on Wednesday, November 7th. The shares were sold at an average price of $21.53, for a total value of $41,746.67. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 2.80% of the stock is currently owned by insiders.
Shares of AngioDynamics stock traded down $0.13 on Wednesday, reaching $20.81. The stock had a trading volume of 1,645 shares, compared to its average volume of 199,012. The company has a current ratio of 2.88, a quick ratio of 1.86 and a debt-to-equity ratio of 0.25. AngioDynamics, Inc. has a fifty-two week low of $15.26 and a fifty-two week high of $24.49. The stock has a market capitalization of $775.42 million, a price-to-earnings ratio of 28.15 and a beta of 0.74.
AngioDynamics (NASDAQ:ANGO) last issued its quarterly earnings data on Friday, January 4th. The medical instruments supplier reported $0.22 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.21 by $0.01. AngioDynamics had a net margin of 5.10% and a return on equity of 5.85%. The business had revenue of $91.50 million during the quarter, compared to analysts’ expectations of $89.24 million. During the same period in the previous year, the company earned $0.16 earnings per share. AngioDynamics’s revenue for the quarter was up 5.5% on a year-over-year basis. As a group, research analysts predict that AngioDynamics, Inc. will post 0.86 earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: This story was first published by Fairfield Current and is the property of of Fairfield Current. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright laws. The original version of this story can be read at https://www.fairfieldcurrent.com/news/2019/01/23/angiodynamics-inc-ango-shares-bought-by-tributary-capital-management-llc.html.
AngioDynamics, Inc designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support.
Receive News & Ratings for AngioDynamics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for AngioDynamics and related companies with MarketBeat.com’s FREE daily email newsletter.